{"schema_version":"secwatch.filing_event.v1","accession":"0001645666-25-000026","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.181802+00:00","generated_at":"2026-05-21T16:12:27.490593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KZR Q1 2025 net loss $16.6M; positive PORTOLA data in AIH","bullets":["Cash $114.4M at March 31, 2025, down from $132.2M at Dec 31, 2024.","Net loss $16.6M ($2.27/share) vs $21.7M ($2.98) in Q1 2024.","PORTOLA Phase 2a: 36% zetomipzomib patients achieved CR with steroid taper vs 0% placebo in relapsed AIH.","R&D expenses fell $5.0M to $12.2M due to PALIZADE trial termination.","Responding to FDA partial clinical hold on PORTOLA; no flares in CR patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001645666-25-000026","json":"https://secwatch.observer/filing/0001645666-25-000026.json","markdown":"https://secwatch.observer/filing/0001645666-25-000026.md","text":"https://secwatch.observer/filing/0001645666-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000164566625000026/0001645666-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000164566625000026/kzr-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:12:27.490593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}